Ideal candidates. Patients who need an oestrogen-free pill, breastfeeding women from 4 weeks postpartum, and patients whose timing may vary by several hours.
Assessment. Medicine, menstrual and breastfeeding history, and blood pressure. No routine pelvic or breast examination or laboratory test is needed. Exclude pregnancy by the usual criteria, with a test if none applies.
Eligibility. The pill categories apply.
- Category 3: current rifampicin or rifabutin; phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine; acute deep vein thrombosis or pulmonary embolism; severe decompensated cirrhosis or liver tumour; lupus with positive or unknown antiphospholipid antibodies; past breast cancer.
- Category 4: current breast cancer.
- Category 2: breastfeeding under 4 weeks; antiretroviral therapy with efavirenz, nevirapine or ritonavir-boosted regimens; past ectopic pregnancy; ischaemic heart disease or stroke; unexplained bleeding before evaluation.
- Category 1: obesity, smoking, hypertension that can be measured and is controlled, HIV, sickle cell disease, migraine without aura.
Interactions. Enzyme inducers lower etonogestrel levels: rifampicin, rifabutin, antiseizure inducers, efavirenz, ritonavir-boosted regimens, griseofulvin, St John’s wort. For short courses, add condoms during treatment and for 28 days after. For long-term use choose DMPA or an intrauterine device.
Counselling. Consent, confidentiality, absence of coercion, and condoms for infection protection. Adolescents under 18 years give assent. Warn that bleeding is unpredictable and amenorrhoea is common.